Acucela’s oral DR drug shows potential for reducing retinal thickness
- Posted on: Jun 28 2018
- Leave a response
An experimental treatment for proliferative diabetic retinopathy, emixustat hydrochloride, has shown promise in a phase 2 trial, according to a press release by Acucela.
Source: AAO
Posted in: Uncategorized